Amylyx Pharmaceuticals, Inc. (AMLX)
- Previous Close
5.36 - Open
5.41 - Bid 3.95 x 200
- Ask 6.77 x 200
- Day's Range
5.22 - 5.53 - 52 Week Range
1.58 - 7.27 - Volume
832,319 - Avg. Volume
895,903 - Market Cap (intraday)
486.71M - Beta (5Y Monthly) -0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-3.10 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.80
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
amylyx.comRecent News: AMLX
View More
Performance Overview: AMLX
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMLX
View MoreValuation Measures
Market Cap
477.80M
Enterprise Value
275.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.72%
Return on Equity (ttm)
-83.24%
Revenue (ttm)
-1.27M
Net Income Avi to Common (ttm)
-218.86M
Diluted EPS (ttm)
-3.10
Balance Sheet and Cash Flow
Total Cash (mrq)
204.07M
Total Debt/Equity (mrq)
0.69%
Levered Free Cash Flow (ttm)
-182.62M
Research Analysis: AMLX
View MoreResearch Reports: AMLX
View MoreDaily – Vickers Top Buyers & Sellers for 09/06/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/24/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.